You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-LAG3 antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Pittsburgh (Nivolumab, Relatlimab, Ipilimumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 31, 2022

Advanced NSCLC Trial (fianlimab, cemiplimab, Placebo)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Mar 27, 2023

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

NSCLC Trial (fianlimab, cemiplimab, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Mar 23, 2023

Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)

Recruiting
  • Large B-cell Lymphoma
  • DLBCL
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 3, 2022

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

Not yet recruiting
  • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 28, 2023

Colorectal Cancer Metastatic Trial (HLX26, HLX10)

Not yet recruiting
  • Colorectal Cancer Metastatic
  • (no location specified)
Oct 14, 2022

Solid Tumor, Adult, Lymphoma Trial in Shanghai (HLX26)

Recruiting
  • Solid Tumor, Adult
  • Lymphoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 10, 2022

Advanced Solid Tumors Trial in Beijing (BMS-986213)

Recruiting
  • Advanced Solid Tumors
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Advanced Malignant Tumors(Stage IA-IB) Trial in Beijing (AK129 IV infusion)

Not yet recruiting
  • Advanced Malignant Tumors(Stage IA-IB)
  • AK129 IV infusion
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Science
Jan 17, 2023

Advanced Solid Tumors Trial in Shanghai (Relatlimab, Nivolumab)

Not yet recruiting
  • Advanced Solid Tumors
  • Relatlimab
  • Nivolumab
  • Shanghai, Shanghai, China
    Local Institution
Aug 10, 2022

Adult Solid Tumor Trial (HLX26, HLX10)

Recruiting
  • Adult Solid Tumor
  • Xuzhou, Jiangsu, China
    Xuzhou Central Hospital
Oct 17, 2022

Cancer Trial in Kashiwa-shi (Relatlimab, Nivolumab)

Active, not recruiting
  • Cancer
  • Kashiwa-shi, Chiba, Japan
    Local Institution
Dec 3, 2021

Solid Tumors, Metastatic Melanoma, NSCLC Trial in Worldwide (RO7247669)

Recruiting
  • Solid Tumors
  • +3 more
  • San Diego, California
  • +20 more
Aug 19, 2022

Advanced Cancer Trial in Worldwide (Relatlimab, Nivolumab, BMS-986205)

Recruiting
  • Advanced Cancer
  • Relatlimab
  • +3 more
  • Duarte, California
  • +23 more
Oct 24, 2022

Tumors by Site Trial in Worldwide (Relatlimab, Nivolumab, BMS-986213)

Active, not recruiting
  • Neoplasms by Site
  • Relatlimab
  • +2 more
  • La Jolla, California
  • +52 more
Feb 10, 2022

Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck Trial in United States (FS118)

Recruiting
  • Advanced Cancer
  • +2 more
  • Los Angeles, California
  • +6 more
Mar 3, 2022

Metastatic Cancer, Solid Tumor, Lymphoma Trial in Canada, United States (Sym021, Sym022, Sym023)

Completed
  • Metastatic Cancer
  • +2 more
  • Grand Rapids, Michigan
  • +3 more
Oct 25, 2022

Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

Recruiting
  • Safety and Efficacy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 27, 2023

Melanoma Trial in Knoxville (Fianlimab, Cemiplimab, Pembrolizumab)

Recruiting
  • Melanoma
  • Knoxville, Tennessee
    University of Tennessee Medical Center
Dec 20, 2022

Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis Trial in Boston, Rochester, Philadelphia

Not yet recruiting
  • Granulomatosis With Polyangiitis
  • +2 more
  • Boston, Massachusetts
  • +2 more
Dec 29, 2022

Psoriasis Trial in Shanghai (608 Q2W, 608 Q4W, Placebo)

Not yet recruiting
  • Psoriasis
  • 608 Q2W
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Huanshan Hospital Fudan University
Sep 8, 2022

NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)

Terminated
Has Results
  • Non-small Cell Lung Cancer
  • Saint Petersburg, Florida
  • +2 more
Oct 22, 2022

Metastatic Cancer, Solid Tumor Trial in Worldwide (Sym021, Sym022, Sym023)

Active, not recruiting
  • Metastatic Cancer
  • Solid Tumor
  • Aurora, Colorado
  • +17 more
Sep 8, 2022

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022